Disease Overview: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and "atypical multiple myeloma." Diagnosis: Tissue biopsy stained with Congo red demonstrating amyloid deposits with applegreen birefringence is required for diagnosis. Invasive organ biopsy is not required because amyloid deposits can be found in bone marrow, salivary gland, or subcutaneous fat aspirate in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory.
| INTRODUCTION
Immunoglobulin light chain (AL) amyloidosis is characterized by a clonal population of bone marrow plasma cells that produces a monoclonal light chain of κ or λ type as either an intact molecule or a Abbreviations: AL amyloidosis, immunoglobulin light chain amyloidosis; dFLC, difference between involved and uninvolved serum free light chain levels; FLC, free light chain; Ig, immunoglobulin; NT-proBNP, N-terminal pro-brain natriuretic peptide; SCT, stem cell transplant; wtTTR, wild type transthyretin
| DISEASE OVERVIEW
Amyloidosis is particularly difficult to diagnose because no single imaging, blood, or urine test is diagnostic for this disorder. 10, 11 The presenting symptoms often mimic those of more common disorders. The diagnosis of AL amyloidosis should be suspected in any patient with nondiabetic nephrotic syndrome; nonischemic cardiomyopathy with "hypertrophy" on echocardiography 12 ; hepatomegaly or increased alkaline phosphatase value with no imaging abnormalities of the liver; chronic inflammatory demyelinating polyneuropathy with a monoclonal protein; or the presence of a monoclonal gammopathy in a patient with unexplained fatigue, edema, weight loss, or paresthesias as illustrated by patient 1. 13 The presence of proteinuria in a patient with a monoclonal gammopathy may be mistaken for multiple myeloma with cast nephropathy. 14 If specific diagnostic evaluation for amyloidosis is not performed, patients with sensory neuropathy may instead undergo treatment for a chronic inflammatory demyelinating polyneuropathy with a monoclonal protein, receiving plasma exchange and immunoglobulin (Ig) infusions. 15 Some patients with unrecognized cardiac amyloidosis and a bone marrow plasma cell percentage <10% are referred to hematologists with a diagnosis of "atypical multiple myeloma." 16 The associated fatigue may be incorrectly ascribed to the mild anemia, the cardiac infiltration goes unrecognized because the patient's ejection fraction is normal (so-called heart failure with preserved ejection fraction), the cardiac silhouette is normal in size, 17 and the ventricular thickening is interpreted as hypertrophy rather than infiltration. 18 Patients with monoclonal gammopathy of undetermined significance or smoldering myeloma that are on active monitoring, who present unwell, with weight loss or fatigue, should raise clinical suspicion of amyloidosis. Routine amyloid staining of the bone marrow is not indicated in a typical patient with MGUS or multiple myeloma. 19 Appropriate screening of a patient with a clinical syndrome compatible with AL amyloidosis would include immunofixation of the serum, 20 immunofixation of the urine, 21 and an Ig FLC assay. 22 The amyloidogenicity of λ Ig light chains is shown in Figure 1 , which compares the findings of serum immunofixation in patients with monoclonal gammopathy of undetermined significance, myeloma, and amyloidosis. The high frequency of λ light chain proteinemia is a hallmark of AL amyloidosis. If immunofixation of serum and urine is negative and the Ig FLC (κ:λ) ratio is normal (0.26-1.65), AL amyloidosis is unlikely and further evaluation should not be undertaken, unless the clinical index of suspicion is very high. 23 An algorithm for the evaluation of a patient with suspected amyloidosis is given in Figure 2 . Normal studies for immunoglobulin abnormalities do not exclude localized or familial amyloidosis.
If a patient has a compatible clinical syndrome and a light chain abnormality is found, biopsy is required to establish the diagnosis.
Biopsy of the clinically involved organ is generally unnecessary. Renal biopsy, 24 endomyocardial biopsy, 25 and liver biopsy are expensive, invasive, and increase the risk of post-biopsy hemorrhage. Biopsy of the iliac crest bone marrow 26 combined with abdominal subcutaneous fat aspiration 27 will identify amyloid deposits in 85% of patients with amyloidosis (Table 1) . A video demonstrating the technique of fat aspiration is available online. 28 Punch biopsy of the fat 29 provides more material for analysis. Minor salivary gland biopsy is also sensitive in the detection of amyloid if experience with fat aspiration is lacking. 30 If both the fat and the bone marrow stain negative for amyloid, there is still a 15% chance that the patient has amyloidosis, and the appropriate organs should be biopsied if the index of suspicion is high. 39 The incidence of MGUS in wild type TTR cardiac amyloidosis is 23%. 40 The light chain origin of an amyloid deposit can be confirmed with immunohistochemistry 41 or an immunogold assay. 42 In AL amyloidosis, a fragment of the light chain is often deposited and may be misfolded so immuno-identification may be equivocal. Mass spectrometry can confirm the amyloid protein composition, and it is considered the standard for typing the protein subunit in amyloid deposits. 43 The technique can be applied to almost any tissue source, including nerves and fat, 44, 45 and it can identify heavy chain as well as light chain amyloidosis. 46 Mass spectroscopy is superior to immunohistochemistry in identifying the protein subunit. 47 
BOX. REQUIRED DIAGNOSTIC EVALUATION AFTER AMYLOIDOSIS IS ESTABLISHED
• Pathologic confirmation that amyloid deposits are of immunoglobulin origin
• Immunoglobulin free light chain κ and λ testing
• Bone marrow biopsy
• Serum and urine immunofixation
• Echocardiography
• 24-hour urine total protein measurement all been shown to be associated with prognosis. 51 Cardiac magnetic resonance imaging is increasingly being used for diagnosis and prognosis of cardiac amyloidosis. Late gadolinium enhancement imaging is highly sensitive and specific with images virtually diagnostic for amyloidosis. 52 The use of radionuclide imaging of the heart with Tc PYP or DPD has been found useful in distinguishing AL cardiac amyloidosis (no uptake) from TTR cardiac amyloidosis (2+ or greater uptake). 53 Tests for serum troponin T and N-terminal pro-brain natriuretic peptide (NT-proBNP) are widely available and are powerful predictors of survival. Survival is also dependent on the size of the plasma cell clone. A staging system for AL amyloidosis is shown in Table 2 . 54 The value of cardiac biomarkers has been validated in patients treated conventionally and those treated with stem cell transplant (SCT). 55 Several studies have demonstrated that patients with advanced cardiac disease should be excluded from SCT studies. 56 High troponin T level predicts early mortality from SCT and can be used as an exclusion criterion for this therapy. 57 Patients with advanced heart failure (NT-proBNP > 8500 pg/L) also are poor candidates for clinical trials of standard agents. 58 High-sensitivity, fifth-generation cardiac troponin T assays at presentation (median survival is 10.6 months if troponin T levels >77 ng/L) and changes in NT-proBNP levels after chemotherapy are reported to be the best predictors of long-term outcome. 59, 60 An excess of early deaths occur in AL amyloidosis for patients with 10% or greater plasma cells at diagnosis. 10 The Ig FLC level at diagnosis, 61 the number of organs involved, 62 Table 2 provides the staging criteria. Translocation t(11;14) is associated with an adverse impact on progression-free survival in contrast to myeloma where it has no impact. 65 T(11;14) also predicts a lower response rate to bortezomib-based therapies. 65 Gain 1q, deletion 14q, and deletion 1p appear to have an adverse prognostic effect. 66 Von Willebrand antigen levels >230 U/dL appear to define a group with a median survival of 2 months. 67 For the purpose of uniform reporting, response criteria were developed for hematologic and organ response. Complete response was defined as negative serum and urine immunofixation results, normal FLC ratio, and normal bone marrow. A partial response was defined as a 50% reduction in difference between involved and uninvolved serum free light chain levels (dFLC). A very good partial response was defined as dFLC <40 mg/L. Cardiac response and progression were defined as an increase or decrease of NT-proBNP of 30% and at least 300 ng/L. To qualify as evaluable for response, NTproBNP levels must be >650 ng/L. 68 Patients with a dFLC <50 mg/L are excluded from most clinical trials because a reliable measurement of 50% reduction does not exist. However these patients have a much better prognosis so ways to include this subgroup in clinical trials of therapy is important. 69 These patients should be held to an endpoint of dFLC <10 mg/L. Depression of uninvolved immunoglobulins also has an independent adverse impact on overall survival. 70 In renal amyloidosis, a 75% reduction in proteinuria is associated with markedly prolonged survival. 71 
| THERAPY
Chemotherapy for the treatment of amyloidosis was introduced in 1972 in the form of melphalan and prednisone. 72 The median survival cardiac troponin T ≥ 0.025 ng/mL; N-terminal pro-brain natriuretic peptide ≥ 1800 pg/mL; and difference between involved and uninvolved serum free light chain levels >180 mg/L. Data from Kumar et al. 46 was 12-18 months. 73 The goal of chemotherapy is normalization of the involved FLC. 74 Therapy remained unchanged until the introduction of SCT. The use of SCT in the management of amyloidosis was logical because it could rapidly eradicate the amyloidogenic light chain produced by the clonal plasma cell populations. 75 Organ response rates of up to 65% have been reported. 76 A prospective randomized study did not demonstrate a survival advantage for patients treated with SCT, 77 and a meta-analysis also questioned the value of SCT for amyloidosis. 78 We have reported benefit in a trial comparing transplantation to melphalan dexamethasone. 79 Patients in these studies
were not risk-stratified, and some may not have been suitable candidates for transplant. 80 The transplant-related mortality rate has fallen to 2.5% since 2009. 81, 82 Good outcomes with SCT have been reported for patients with cardiac amyloidosis diagnosed before the onset of advanced congestive heart failure. The hematologic and cardiac response rates were 66% and 41%, respectively, and hematologic response predicted survival. 54 The introduction of plerixafor has made mobilization possible for virtually all eligible patients. 83, 84 Registry data show reduced therapy-related mortality and 77% 5-year survival.
Outcomes were better at centers performing four AL transplants annually.
85
The 10-year survival after SCT is 25%, and the 10-year survival rate was 53% for patients with a complete response to treatment. 86 Ten-year survival rate of all patients at our center is 43%. 87 Transplant-related mortality rates have decreased from as high as 40% to 4% to 7% in current studies. 88, 89 Extended follow-up of 69 patients enrolled in an SCT trial reported a median survival of 96 and 120 months for the transplanted cohort. 90 Hematologic relapse occurs at a median of 4 years. The median survival in patients with hematologic relapse after an initial CR is 8.5 years after relapse.
91
Excluding patients from SCT whose NT-proBNP levels are > 5000 pg/mL can reduce therapy-related mortality rates to 1%. 81 Renal and cardiac organ responses and high complete hematologic response rates have been reported after SCT. 92 No more than 20%-25% of patients are eligible for transplant. However, response to bortezomib can render one-third of initially transplant-ineligible patients capable of undergoing SCT. 93 Currently, a hematologic response is achievable in 76% of eligible patients, which is complete in 39%. 94 At Mayo Clinic, organ responses have been recorded in 47% of patients.
94
Hematologic response is the strongest predictor of outcome. 92 In an analysis that excluded both early deaths and patients who were unevaluable for response at six months, 95 the significance of depth of hematologic response for predicting survival persisted. Remission of proteinuria is not always followed by resolution of amyloid deposits, suggesting that the light chains, rather than amyloid fibrils, directly injure the glomerulus. 96 SCT should remain an important consideration for patients who are eligible to undergo this technique safely.
There is evidence that induction before SCT improves outcomes. 97 Bortezomib followed by SCT resulted in 3-year PFS and OS of 58% and 77%, respectively. 98 In a randomized trial of induction versus no induction, the survival rates at 24 months post-treatment start were 95.0% in the bortezomib + HDM/SCT group and 69.4% in the HDM/SCT alone group (P = .03). 99 Patients with AL amyloidosis who have more than 10% marrow plasma cells have a poor prognosis and could potentially benefit from induction chemotherapy. 100 Changes in light chain levels are a better predictor of outcome than changes in the intact Ig levels. 101 
| CONVENTIONAL TREATMENT OF AMYLOIDOSIS
Melphalan and prednisone have been demonstrated to be superior therapy to colchicine in two randomized phase III studies. [102] [103] [104] Melphalan and dexamethasone have been combined in the treatment of AL amyloidosis. Of 46 patients who were ineligible for SCT, organ response after treatment with melphalan and dexamethasone was seen in 48% of patients with a low treatment-related mortality rate of only 4%. At 6 years, the actuarial survival was approximately 50%, and the progression-free survival was 40%. 105, 106 Alkylator-based chemotherapy has been reported to be effective in almost two-thirds of patients. 107 However, 2 other reports using the identical regi- Melphalan plus dexamethasone is still considered a standard treatment for nonstudy, nontransplant intervention because of its low-toxicity profile, its demonstrated ability to produce hematologic responses even in the presence of advanced disease, and the oral availability of both agents. 112 A summary of regimens used in the treatment of amyloidosis is given in Table 3 .
| NOVEL AGENTS IN THE TREATMENT OF AMYLOIDOSIS

| Thalidomide
In the first study of thalidomide therapy for AL amyloidosis, 16 patients were treated and no organ responses were seen. 113 In a subsequent study, hematologic responses were reported in 48% of patients, with 19% having complete hematologic responses, but treatment-related toxicity was frequent and the agent was poorly tolerated. 114 Thalidomide has been combined with melphalan and dexamethasone in 22 patients, resulting in 8 hematologic and 4 organ responses. 106 Thalidomide has also been combined with cyclophosphamide and dexamethasone, with a hematologic response rate of 74% and complete response in 21% of patients. 115 Median overall survival from the start of therapy was 41 months, median progression-free survival was 32 months, and treatment-related mortality was 3%. Current recommendations suggest starting thalidomide at a dose not higher than 50 mg. Dose can be increased if tolerated. 62 At Mayo Clinic, this agent is rarely used.
| Lenalidomide
Lenalidomide has been combined with dexamethasone in the treatment of AL amyloidosis. Toxicities include cytopenias, rash, fatigue, and cramps. 116 In the first of two published studies, the hematologic response rate was 41%, and the median response duration and overall survival were 19.2 and 31 months, respectively. 58 In the second study, the response rate was 67%. 117 Of the patients with renal involvement, 41% had a decrease in urinary protein excretion of more than 50%
with no decrease in renal function. Response duration and overall survival were not reported. 117 High-risk patients were less likely to respond to lenalidomide.
Lenalidomide has been combined with melphalan and dexamethasone for patients with newly diagnosed AL amyloidosis. In a phase I-II dose-escalation study, the maximum tolerated dose of lenalidomide was 15 mg when combined with melphalan and dexamethasone. 118 Hematologic responses were seen in 58% and were complete in 42%.
The 2-year, event-free and overall survivals were 54% and 81%, respectively. 118 In a phase 2 study, melphalan, lenalidomide, and dexamethasone produced a 50% response rate, with 7% having a complete response, but the regimen was associated with significant myelosuppression. 119 In a trial of lenalidomide (10 mg), melphalan (0.18 mg/kg for 4 days), and dexamethasone (40 mg weekly), with 22 of 25 patients having stage II or III cardiac amyloidosis, the 1-year survival rate was 58%. Organ responses were seen in 8%. Cardiac arrhythmias were seen in 33%. 120 Lenalidomide has been combined with cyclophosphamide and dexamethasone in 35 patients. 121 The median number of treatment cycles was 6. The hematologic response rate was 60% and, in those receiving at least four cycles, the response rate was 87%. The median overall survival was 37.8 months, and similar results were reported with the use of lenalidomide, cyclophosphamide, and dexamethasone, with an 8% complete response rate and a 2-year survival rate of 41%.
As salvage therapy in relapsing disease, cyclophosphamide, lenalidomide, and dexamethasone (CRd) can produce a 62% response rate. [121] [122] [123] In newly diagnosed patients receiving CRd, a hematologic response rate of 46% and organ response of 46% was reported. 124 In patients with amyloidosis, lenalidomide can frequently worsen kidney function, even for patients whose amyloidosis spares the kidney.
Recovery was reported in only 44%. 125 Lenalidomide-treated patients had a higher risk of rising NT-proBNP levels. This is commonly associated with clinical deterioration of the patient. Lenalidomide should not be used as first-line therapy in patients with cardiac involvement. 126 Lenalidomide salvage therapy after bortezomib or melphalan treatment failures has been reported to achieve a hematologic response rate of 41%. 127 Lenalidomide is a legitimate second-line therapy if caution in cardiac amyloid patients is exercised.
| Pomalidomide
Pomalidomide, a derivative of thalidomide with structural similarity to both thalidomide and lenalidomide, was administered to 29 patients. 128 Twenty-eight had previously received alkylating agents, as well as autologous SCT in 13, prior lenalidomide or thalidomide in 15, and prior bortezomib in 12. All patients were evaluable for hematologic response with a response rate of 38%. Three patients had very good partial responses, and three and four patients had confirmed and unconfirmed organ responses, respectively. 128 One-year progression-free survival and overall survival rates were 59% and 76%, respectively. Pomalidomide and dexamethasone is a promising therapy for AL amyloidosis. As with lenalidomide, cardiac amyloidosis patients tolerate this agent poorly with clinical deterioration commonly reported by patients.
| Bortezomib
In an early study of bortezomib, 80% of evaluable patients had a hematologic response. 129 131 Patients with New York Heart Association class III-IV heart disease were excluded. There were no treatment-related deaths.
Hematologic responses were seen in 50% of patients, 20% of which were complete responses; median time to response was 1.2 months.
Bortezomib has been reported to successfully improve cardiac function in AL amyloidosis. 132 Combination bortezomib and dexamethasone has been used after SCT to improve the depth of response. 139 It is not proven that addition of cyclophosphamide to bortezomib-dexamethasone significantly impacts response or survival. 140 Combinations of novel agents are being reported. In one study, 7 of 9 in a case series received bortezomib, cyclophosphamide, or lenalidomide/thalidomide, and dexamethasone.
Hematologic and organ response was seen in 89% and 78% of patients, respectively. A survey of European centers using Cybor-d in newly diagnosed patients reported a response rate of 60% but a median survival of advanced cardiac patients of only seven months. 139 Bortezomib-melphalan-prednisone (VMP) in newly diagnosed AL produces an 84% hematologic response rate. 141 Unfortunately, neuropathy was reported in 44%. 142 The non-neurotoxic proteosome inhibitor Ixazomib in relapserefractory AL produced hematologic response in 52% and organ response in 56% at a dose of 4 mg by mouth weekly. 143 Bendamustine is currently being explored for its activity in AL amyloidosis. 144 There has been one report of Venetoclax therapy for amyloidosis with t(11;14). Figure 3A ,B shows chemotherapy algorithms recommended for patients with newly diagnosed AL amyloidosis (stratified by transplant eligibility). For patients who achieve a complete hematologic response, kidney transplantation can be successful (80% graft survival at 42 months). 148 Renal transplantation is feasible in AL. 149 Selection should exclude patients with extrarenal amyloid deposition, and the underlying clonal plasma cell disorder ideally should be controlled. 150 Median graft survival of 8.9 years is reported when amyloid precursor protein production is reduced. In a registry series, 8 46 patients received renal allografts. A total of 5-and 10-year graft survival rates were 45% and 26%, respectively. Amyloid recurrence was proven in 16%.A summary of non-transplant therapies is given (Table 3) .
Cardiac transplantation can also be performed, but strict control of the plasma cell population is required to prevent subsequent amyloid deposition. Nine AL patients are all alive with only one amyloid recurrence in the graft. The fibril-reactive mAb 11-1F4, when labeled with iodine-124 was shown to bind AL amyloid in patients by using PET/CT imaging and is being studied NCT02245867.
| CONCLUSION
When AL amyloidosis is diagnosed before the development of advanced cardiomyopathy, patients can achieve both hematologic and organ responses after chemotherapy, which translates into prolonged survival. The best predictor of organ response is a deep hematologic response. 155 A patient with a compatible syndrome that suggests amyloidosis should have testing with immunofixation and FLC assessment followed by bone marrow and fat biopsies to establish the diagnosis. Once the amyloidosis is confirmed to be of light chain origin, patients should be considered for SCT (only a minority are eligible) or trials of systemic chemotherapy. Active agents include corticosteroids (dexamethasone, prednisone), alkylating agents (melphalan, cyclophosphamide), immunomodulatory drugs (thalidomide, lenalidomide), proteasome inhibitors (bortezomib), and daratumumab. Antibodies against amyloid deposits are a potential new therapeutic strategy.
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